China Resources Double-Crane adjusts fund, secures drug procurement bids

China Resources Double-Crane Pharmaceutical announced key adjustments to its industrial fund. The company will now contribute 8,300,000 yuan to the China Resources Double-Crane Biomedical Industrial Fund, with its subsidiary no longer participating. The fund’s total capital remains 50,000,000 yuan, and the investment decision-making mechanism now requires unanimous consent from all five members.

In related news, China Resources Double-Crane Pharmaceutical and its subsidiaries successfully secured bids in the 11th batch of national centralized drug procurement. Key products include methoxylchlorpramide injection, mesocarbamol injection, famotidine injection, and piracetam tablets. While methoxylchlorpramide injection and mesocarbamol injection have not yet generated sales in 2024, famotidine injection had 2024 sales of 5,480,700 yuan and piracetam tablets had 124,100 yuan. Other participating drugs did not make the final selection.

These procurement agreements are expected to boost the company's market share and brand influence, positively impacting future operating performance, with the procurement period extending until December 31, 2028.